Filing Flows › Starling Oncology (STLN) › Q3 2026
Starling Oncology (STLN) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 6, 2026
Starling Oncology (STLN) reported revenue of $170M for the third quarter 2026 (Q3 2026), +24% from a year earlier and +5% from the quarter before. Operating margin was -1.8%, net loss $15.7M (9.3% of revenue).
Starling Oncology, Q3 2026: revenue $170M (+24% year over year), operating margin -1.8%, net loss $15.7M, operating cash flow $10.1M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $170M | +5% | +24% |
| Operating profit | −$3.0M | — | — |
| Net earnings | −$15.7M | — | — |
| Operating cash flow | $10.1M | -15% | — |
| Free cash flow | $8.9M | -20% | — |
What changed
Revenue was $169.8M in Q3 2026, up 24% year over year and up 5% from the previous quarter. Specialty Pharmacy was the largest line at 64% of revenue. Specialty Pharmacy added $33.4M year over year (up 44%), 101% of the total change. FFS revenue declined 21%.
Operating costs exceeded revenue by $3.0M, an operating margin of -1.8%. Total costs grew 19% against revenue growth of 24%. The fastest-growing cost line was SG&A (+27%). The quarter ended with a net loss of $15.7M, wider than the previous quarter's $9.8M loss. Net interest and other expense of $12.8M was the main reason.
Operating cash flow was $10.1M. Non-cash charges added back $1.5M of depreciation and amortization and $1.3M of share-based compensation. Working capital and other items added $23.0M. Capital expenditures of $1.3M left free cash flow of $8.9M.
Questions
What was Starling Oncology's revenue in the third quarter 2026?
Starling Oncology (STLN) reported revenue of $170M for the third quarter 2026 (Q3 2026), +24% from a year earlier and +5% from the quarter before.
Was Starling Oncology profitable in the third quarter 2026?
Operating loss was $3.0M (-1.8% of revenue) and net loss $15.7M.
Source: Starling Oncology 10-Q on SEC EDGAR.